Chart-Typ:
Zeitraum:
| Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen |
| Gilead's Kite, Arcellx Expand Partnership | FOSTER CITY (dpa-AFX) - Kite, a Gilead Company (GILD) Wednesday announced expansion of its partnership with Arcellx, Inc. (ACLX) by investing in Arcellx's ACLX001 ARC-SparX program in multiple... ► Artikel lesen |
| Arcellx, Inc.: Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights | -- Recently released ASH abstract for the company's Phase 1 CART-ddBCMA trial demonstrated that median duration of response, progression free survival, and overall survival not reached with median... ► Artikel lesen |
| Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen |
| Aktien New York: Dow erholt sich vor Start in die Berichtssaison | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben sich am Donnerstag im Handelsverlauf von ihrer anfänglichen Schwächephase erholt. Der Dow Jones Industrial notierte zuletzt 0,12 Prozent im Plus bei 38... ► Artikel lesen |
| ROUNDUP/Aktien New York: Dow schwächer vor Start in die Berichtssaison | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf zur Wochenmitte hat die Wall Street am Donnerstag daran angeknüpft. Dagegen verzeichnete die Technologiebörse Nasdaq eine freundliche Tendenz.... ► Artikel lesen |
| SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen |
| SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN | STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced... ► Artikel lesen |
| SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors | Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
